XPO1 and melanoma: Selinexor, a selective inhibitor of exportin 1, additionally provided evidence of efficacy on its own in solid tumor xenografts including kidney, pancreas, prostate, breast, lung, melanoma, colon, gastric, and ovarian cancers, neuroblastoma, and sarcomas.